

July 24, 2003  
Shionogi & Co., Ltd.

**Announcement of Change of Launch Schedule for  
New Treatment for Hyperlipidemia Rosuvastatin Calcium**

Rosuvastatin Calcium, a treatment for hyperlipidemia discovered by Shionogi & Co., Ltd. <Shionogi> (President: Motozo Shiono), was licensed out to AstraZeneca of the UK in April 1998, and it has been developed by AstraZeneca in various countries of the world. The product has already been launched in several countries. In Japan, AstraZeneca K.K.<AZKK> (President: Martin Wright) has undertaken its development, and filed an NDA with the MHLW in April 2002. Also, in May 2002 AZKK and Shionogi signed an agreement to co-market the product in Japan.

Regarding launch of Rosuvastatin Calcium in Japan, AZKK and Shionogi have been making various preparations assuming launch to take place before the end of Fiscal Year 2003. However, we have recently been informed by AZKK, the applicant for import approval, that judging from the progress of regulatory review of the product they have reached a view that it is difficult to launch during the Fiscal Year 2003. We would like to inform that, based on this, we at Shionogi have also changed Rosuvastatin launch schedule to the first half of Fiscal Year 2004.

This announcement has been co-ordinated with AstraZeneca and is timed in to happen at the same time as their Half-Year Results announcement taking place today.

[ For Further Information ]

Shionogi & Co., Ltd., Public Relations Unit

Osaka           TEL: +81-6-6209-7885   FAX: +81-6-6229-9596

Tokyo           TEL: +81-3-3406-8164   FAX: +81-3-3406-8099